Effect of methotrexate on blood purine and pyrimidine levels in patients with rheumatoid arthritis

Rheumatology

Volumn 38, Issue 10, 1999, Pages 997-1002

  Smolenska Z ^a   Kaznowska, Z ^a   Zarowny D ^a   Simmonds, H A ^c   Smolenski R T ^b  

^a INSTITUTE OF RHEUMATOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c GUY S HOSPITAL   (United Kingdom)

Author keywords

Adenosine; Methotrexate; Purines; Pyrimidines; Rheumatoid arthritis; Uric acid

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE; ADENOSINE; CYTOKINE; HYPOXANTHINE; METHOTREXATE; NUCLEOSIDE; NUCLEOTIDE; PURINE; PYRIMIDINE; URIC ACID; URIDINE;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CELL PROLIFERATION; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DNA SYNTHESIS; ERYTHROCYTE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOCOMPETENT CELL; METABOLITE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PURINE SYNTHESIS; PYRIMIDINE SYNTHESIS; RHEUMATOID ARTHRITIS; RNA SYNTHESIS; TIME; VENOUS BLOOD;

ADENOSINE; ADENOSINE TRIPHOSPHATE; ADULT; AMINOIMIDAZOLE CARBOXAMIDE; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHRONIC DISEASE; CYTIDINE TRIPHOSPHATE; ERYTHROCYTES; FEMALE; GUANOSINE TRIPHOSPHATE; HUMANS; HYPOXANTHINE; METHOTREXATE; MIDDLE AGED; RIBONUCLEOTIDES; URIC ACID; URIDINE;

EID: 0032722979     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/38.10.997     Document Type: Article

References (27)

1. Farber S, Toch E, Manning-Sears E, Pinkel D. Advances in chemotherapy of cancer in man. In: Greenstein HA, ed. Advances in cancer research. New York: Academic Press, 1956:2-73.
2. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312:818-22.
3. Bookbinder SA, Espinoza LR, Fenske NA, Germain BF et al. Methotrexate: its use in the rheumatic diseases. Clin Exp Rheumatol 1984;2:185-93.
4. Baggott JE, Morgan SL, Ha TS, Alarcon GS et al. Antifolates in rheumatoid arthritis: a hypothetical mechanism of action. Clin Exp Rheumatol 1993;11(suppl. 8): S101-5.
5. Cronstein BN, Eberle MA, Gruber HE, Levin RI. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci USA 1991;88:2441-5.
6. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993;92: 2675-82.
7. Morabito L, Montesinos MC, Schreibman DM, Balter L et al. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5′-nucleotidase-mediated conversion of adenine nucleotides. J Clin Invest 1998;101:295-300.
8. Gao IK, Leins C, Bohlen H, Heilig B et al. Inhibition of interleukin-8 synthesis by intraarticular methotrexate therapy in patients with rheumatoid arthritis. Z Rheumatol 1998;57:95-100.
9. Dolhain RJ, Tak PP, Dijkmans BA, De Kuiper P et al. Methotrexate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis. Br J Rheumatol 1998;37:502-8.
10. Morgan SL, Baggott JE, Lee JY, Alarcon GS. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J Rheumatol 1998; 25:441-6.
11. Nesher G, Osborn TG, Moore TL. Effect of treatment with methotrexate, hydroxychloroquine, and prednisone on lymphocyte polyamine levels in rheumatoid arthritis: correlation with the clinical response and rheumatoid factor synthesis. Clin Exp Rheumatol 1997;15:343-7.
12. Genestier L, Paillot R, Fournel S, Ferraro C et al. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 1998;102:322-8.
13. Smolenski RT, Lachno DR, Ledingham SJM, Yacoub MH. Determination of sixteen nucleotides, nucleosides and bases using high-performance liquid chromatography and its application to the study of purine metabolism in hearts for transplantation. J Chromatogr 1990;527:414-20.
14. Smolenski RT, Yacoub MH. Liquid Chromatographic evaluation of purine production in the donor human heart during transplantation. Biomed Chromatogr 1993; 7:189-95.
15. Smolenski RT, Montero C, Duley J, Simmonds HA. Effects of adenosine analogues on ATP concentration in human erythrocytes. Further evidence for a route independent of adenosine kinase. Biochem Pharmacol 1991;42:1767-73.
16. Lyons SD, Christopherson RI. Antifolates induce primary inhibition of the de novo purine pathway prior to 5-aminoimidazole-4-carboxamide ribotide transformylase in leukemia cells. Biochem Int 1991;24:187-97.
17. Pui CH, Relling MV, Lascombes F, Harrison PL et al. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia 1997;11:1813-6.
18. Simmonds HA, Fairbanks LD, Morris GS, Webster DR et al. Altered erythrocyte nucleotide patterns are characteristic of inherited disorders of purine or pyrimidine metabolism. Clin Chim Acta 1988;171:197-210.
19. Herbert KE, Bhusate LL, Scott DL, Perrett D. Purine metabolism in arthritis: 1. Synovial fluid adenosine concentrations are low in rheumatoid arthritis. Int J Pur Pyr Res 1999;2:31-4.
20. Smolenski RT, Kalsi K, Zych M, Kochan Z et al. Adenine/ ribose supply increases adenosine production and protects ATP pool in adenosine kinase inhibited cardiac cells. J Mol Cell Cardiol 1998;30:673-83.
21. Barankiewicz J, Jimenez J, Uyesaka J, Gruber HE. Regulation of adenosine concentration by acadesine (AICA-Riboside) in human B-lymphoblasts. Adv Exp Med Biol 1991;309A:275-8.
22. Kalsi KK, Smolenski RT, Yacoub MH. Effects of nucleoside transport inhibitors and adenine/ribose supply on ATP concentration and adenosine production in cardiac myocytes. Mol Cell Biochem 1998;180:193-9.
23. Smits GJ, McVey M, Cox BF, Perrone MH et al. Cardioprotective effects of the novel adenosine A1/A2 receptor agonist AMP 579 in a porcine model of myocardial infarction. J Pharmacol Exp Ther 1998;286:611-8.
24. McKendry RJ. The remarkable spectrum of methotrexate toxicities. Rheum Dis Clin North Am 1997;23:939-54.
25. Liegler DG, Henderson ES, Hahn MA, Oliveiro VT. The effect of organic acids on renal clearance of methotrexate in man. Clin Pharmacol Ther 1969;10:849-57.
26. Kremer JM. Possible mechanisms of action of methotrexate in patients with rheumatoid arthritis. Br J Rheumatol 1995;34(suppl. 2):26-9.
27. Yamanaka H, Togashi R, Hakoda M, Terai C et al. Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment. Adv Exp Med Biol 1998;431:13-8.